CU24188B1 - Composición vacunal contra el virus dengue - Google Patents
Composición vacunal contra el virus dengueInfo
- Publication number
- CU24188B1 CU24188B1 CUP2012000179A CU20120179A CU24188B1 CU 24188 B1 CU24188 B1 CU 24188B1 CU P2012000179 A CUP2012000179 A CU P2012000179A CU 20120179 A CU20120179 A CU 20120179A CU 24188 B1 CU24188 B1 CU 24188B1
- Authority
- CU
- Cuba
- Prior art keywords
- seq
- compositions
- vaccine composition
- oligonucleotide identified
- immune response
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 208000001490 Dengue Diseases 0.000 title 1
- 206010012310 Dengue fever Diseases 0.000 title 1
- 241000700605 Viruses Species 0.000 title 1
- 208000025729 dengue disease Diseases 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 241000725619 Dengue virus Species 0.000 abstract 1
- 101710091045 Envelope protein Proteins 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 101710188315 Protein X Proteins 0.000 abstract 1
- 102100021696 Syncytin-1 Human genes 0.000 abstract 1
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 210000000234 capsid Anatomy 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención provee composiciones vacunales que comprenden al menos un antígeno basado en la proteína de la cápsida del virus dengue(VD) y el oligonucleótido identificado como SEQ ID NO. 1. La composición vacunal que comprende una proteína de fusión formada por la cápsida del VD2 y el dominio III de la proteína de la envoltura del mismo serotipo, agregada con el oligonucleótido identificado como SEQ ID NO. 1,genera los mayores niveles de respuesta inmune celular y protección en ratones, al compararla con la generada por formulaciones del mismo antígeno agregado con oligonucleótidos de potencial de capacidad adyuvante,reportados en la literatura.La efectividad de las composiciones que comprenden el oligonucleótido identificado como SEQ ID NO.1 se demostró, además, en primates no humanos.Las composiciones de la invención pueden ser monovalentes,bivalentes y tetravalentes, y se combinan en diferentes regímenes de inmunización para inducir respuesta inmune funcional frente a los cuatro serotipos virales.
Priority Applications (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CUP2012000179A CU24188B1 (es) | 2012-12-27 | 2012-12-27 | Composición vacunal contra el virus dengue |
| US14/655,227 US9463235B2 (en) | 2012-12-27 | 2013-12-16 | Dengue virus vaccine composition |
| ES13823919T ES2721921T3 (es) | 2012-12-27 | 2013-12-16 | Composición de vacuna del virus del dengue |
| KR1020157015888A KR102203759B1 (ko) | 2012-12-27 | 2013-12-16 | 뎅기 바이러스 백신 조성물 |
| EP13823919.9A EP2939691B1 (en) | 2012-12-27 | 2013-12-16 | Dengue virus vaccine composition |
| BR112015015138-8A BR112015015138B1 (pt) | 2012-12-27 | 2013-12-16 | Composição de vacina contra o vírus da dengue, ácido nucleico e uso dos mesmos |
| AU2013369626A AU2013369626B2 (en) | 2012-12-27 | 2013-12-16 | Dengue virus vaccine composition |
| CN201380068237.7A CN104936616B (zh) | 2012-12-27 | 2013-12-16 | 针对登革病毒的疫苗组合物 |
| PCT/CU2013/000008 WO2014101903A1 (es) | 2012-12-27 | 2013-12-16 | Composicion vacunal contra el virus dengue |
| MX2015008482A MX367424B (es) | 2012-12-27 | 2013-12-16 | Composicion vacunal contra el virus dengue. |
| CA2894134A CA2894134C (en) | 2012-12-27 | 2013-12-16 | Dengue virus vaccine composition |
| SG11201505170WA SG11201505170WA (en) | 2012-12-27 | 2013-12-16 | Dengue virus vaccine composition |
| JP2015549988A JP6333290B2 (ja) | 2012-12-27 | 2013-12-16 | デングウイルスワクチン組成物 |
| MYPI2015702127A MY190698A (en) | 2012-12-27 | 2013-12-16 | Dengue virus vaccine composition |
| ARP130104975A AR094238A1 (es) | 2012-12-27 | 2013-12-20 | Composicion vacunal contra el virus dengue |
| PH12015501446A PH12015501446A1 (en) | 2012-12-27 | 2015-06-22 | Dengue virus vaccine composition |
| HK15110603.1A HK1209647A1 (en) | 2012-12-27 | 2015-10-28 | Dengue virus vaccine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CUP2012000179A CU24188B1 (es) | 2012-12-27 | 2012-12-27 | Composición vacunal contra el virus dengue |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20120179A7 CU20120179A7 (es) | 2014-08-28 |
| CU24188B1 true CU24188B1 (es) | 2016-07-29 |
Family
ID=49999644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2012000179A CU24188B1 (es) | 2012-12-27 | 2012-12-27 | Composición vacunal contra el virus dengue |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9463235B2 (es) |
| EP (1) | EP2939691B1 (es) |
| JP (1) | JP6333290B2 (es) |
| KR (1) | KR102203759B1 (es) |
| CN (1) | CN104936616B (es) |
| AR (1) | AR094238A1 (es) |
| AU (1) | AU2013369626B2 (es) |
| BR (1) | BR112015015138B1 (es) |
| CA (1) | CA2894134C (es) |
| CU (1) | CU24188B1 (es) |
| ES (1) | ES2721921T3 (es) |
| HK (1) | HK1209647A1 (es) |
| MX (1) | MX367424B (es) |
| MY (1) | MY190698A (es) |
| PH (1) | PH12015501446A1 (es) |
| SG (1) | SG11201505170WA (es) |
| WO (1) | WO2014101903A1 (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22683A1 (es) * | 1997-01-15 | 2001-07-20 | Inst De Medicina Tropical Pedro Kouri | Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos |
| CU23245A1 (es) * | 2001-07-16 | 2007-10-17 | Inst De Medicina Tropical Pedr | CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS |
| EP1614426B1 (en) * | 2003-02-20 | 2008-12-17 | Centro Nacional De Investigaciones Cientificas (CNIC) | Attenuated strains of vibrio cholerae and lyophilised vaccines containing same |
| CU23578A1 (es) * | 2005-09-16 | 2010-09-30 | Ct Ingenieria Genetica Biotech | Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal |
| CU23586A1 (es) * | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
| CU20080028A6 (es) * | 2008-02-29 | 2011-02-24 | Ct Ingenieria Genetica Biotech | Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus |
-
2012
- 2012-12-27 CU CUP2012000179A patent/CU24188B1/es active IP Right Grant
-
2013
- 2013-12-16 JP JP2015549988A patent/JP6333290B2/ja active Active
- 2013-12-16 KR KR1020157015888A patent/KR102203759B1/ko active IP Right Grant
- 2013-12-16 EP EP13823919.9A patent/EP2939691B1/en active Active
- 2013-12-16 CN CN201380068237.7A patent/CN104936616B/zh active Active
- 2013-12-16 MX MX2015008482A patent/MX367424B/es active IP Right Grant
- 2013-12-16 AU AU2013369626A patent/AU2013369626B2/en not_active Ceased
- 2013-12-16 CA CA2894134A patent/CA2894134C/en active Active
- 2013-12-16 SG SG11201505170WA patent/SG11201505170WA/en unknown
- 2013-12-16 BR BR112015015138-8A patent/BR112015015138B1/pt active IP Right Grant
- 2013-12-16 ES ES13823919T patent/ES2721921T3/es active Active
- 2013-12-16 WO PCT/CU2013/000008 patent/WO2014101903A1/es active Application Filing
- 2013-12-16 US US14/655,227 patent/US9463235B2/en active Active
- 2013-12-16 MY MYPI2015702127A patent/MY190698A/en unknown
- 2013-12-20 AR ARP130104975A patent/AR094238A1/es not_active Application Discontinuation
-
2015
- 2015-06-22 PH PH12015501446A patent/PH12015501446A1/en unknown
- 2015-10-28 HK HK15110603.1A patent/HK1209647A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2894134C (en) | 2021-04-06 |
| PH12015501446B1 (en) | 2015-09-14 |
| JP6333290B2 (ja) | 2018-05-30 |
| CN104936616B (zh) | 2017-06-20 |
| JP2016505004A (ja) | 2016-02-18 |
| KR20150100660A (ko) | 2015-09-02 |
| EP2939691A1 (en) | 2015-11-04 |
| KR102203759B1 (ko) | 2021-01-18 |
| WO2014101903A1 (es) | 2014-07-03 |
| ES2721921T3 (es) | 2019-08-06 |
| SG11201505170WA (en) | 2015-08-28 |
| AU2013369626B2 (en) | 2017-07-27 |
| BR112015015138A2 (es) | 2017-08-15 |
| MY190698A (en) | 2022-05-11 |
| US20150328304A1 (en) | 2015-11-19 |
| US9463235B2 (en) | 2016-10-11 |
| CA2894134A1 (en) | 2014-07-03 |
| MX2015008482A (es) | 2015-09-23 |
| PH12015501446A1 (en) | 2015-09-14 |
| MX367424B (es) | 2019-08-21 |
| BR112015015138B1 (pt) | 2022-05-17 |
| EP2939691B1 (en) | 2019-02-20 |
| HK1209647A1 (en) | 2016-04-08 |
| CU20120179A7 (es) | 2014-08-28 |
| CN104936616A (zh) | 2015-09-23 |
| AR094238A1 (es) | 2015-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118003T1 (el) | Αναπτυξη συστατικων εμβολιου ιου δαγκειου | |
| AR069882A1 (es) | Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e | |
| HRP20190876T1 (hr) | Novi adjuvantirani pripravci | |
| CO2018005265A2 (es) | Vacunas de ácido nucleico para el virus varicela-zóster | |
| UY35131A (es) | Composiciones, métodos y usos de construcciones de virus del dengue de serotipo-4 | |
| EA201591888A1 (ru) | Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов | |
| MX2013004159A (es) | Proteina vp6 de la capside de norovirus y de rotavirus para el uso como vacuna combinada. | |
| PE20140646A1 (es) | Vacuna de virus de dengue inactivado | |
| EA201891460A1 (ru) | Композиция дендритных клеток | |
| CO6430434A2 (es) | Nuevas composiciones de vacunas con pertussis acelular y método de fabricación de las mismas | |
| NZ630869A (en) | Compositions and methods for dengue virus chimeric constructs in vaccines | |
| AR080111A1 (es) | Metodos y composiciones de inmunizacion | |
| MX2018010958A (es) | Vacuna para virus de zika atenuado vivo. | |
| UY32274A (es) | Pestivirus quimericos | |
| NZ618158A (en) | Compositions and methods for administration of vaccines against dengue virus | |
| MX2021015972A (es) | Vacuna contra la fiebre aftosa. | |
| CO7461133A2 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
| CO6541529A2 (es) | Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos | |
| PH12015502666A1 (en) | Dengue virus vaccine compositions and methods of use thereof | |
| PH12017501165A1 (en) | Dengue virus vaccine compositions and methods of use thereof | |
| CO6700818A2 (es) | Vectores de parapoxvirus | |
| UY33400A (es) | Vectores de parapoxvirus | |
| EA201500140A1 (ru) | Ослабленные вакцины от свиного гриппа и способы их получения и применения | |
| CU20120179A7 (es) | Composición vacunal contra el virus dengue | |
| UY32876A (es) | Régimen de inmunización por sensibilización-refuerzo heteróloga |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant of patent |